Progression of esophageal dysplasia to cancer

Annals of the New York Academy of Sciences

Volumn 1325, Issue 1, 2014, Pages 96-107

  Appelman, Henry D ^a   Matejcic, Marco ^b   Parker, M Iqbal ^b   Riddell, Robert H ^c   Salemme, Marianna ^d   Swanson, Paul E ^e   Villanacci, Vincenzo ^d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c MOUNT SINAI HOSPITAL   (Canada)

^d SPEDALI CIVILI   (Italy)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; Lectin; OESO; P52; Racemase

Indexed keywords

EPIDERMAL GROWTH FACTOR; LECTIN; PROTEIN P16; PROTEIN P52; PROTEIN P53; RACEMASE; GLYCOPROTEIN;

ARTICLE; BOWEN DISEASE; CANCER GRADING; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS DYSPLASIA; ESOPHAGUS MUCOSA; ESOPHAGUS ULCER; FAT INTAKE; GASTROESOPHAGEAL REFLUX; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; GLYCOBIOLOGY; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; INCIDENCE; INVASIVE CARCINOMA; LOW GRADE GLANDULAR DYSPLASIA; LOW GRADE SQUAMOUS DYSPLASIA; OBESITY; OVERNUTRITION; P53 IMMUNOREACTIVE GLANDULAR DYSPLASIA; PREVALENCE; PROTEIN EXPRESSION; SMOKING; TUMOR INVASION; ANIMAL; BARRETT ESOPHAGUS; BLOOD; COMPLICATION; ESOPHAGEAL NEOPLASMS; FRANCE; PATHOLOGY;

ANIMALS; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; GLYCOPROTEINS; HUMANS; NEOPLASM INVASIVENESS; PARIS;

EID: 84926111144     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12523     Document Type: Article

References (48)

1. Shimizu, M., G. Zaninotto, K. Nagata, et al. 2013. Esophageal squamous cell carcinoma with special reference to its early stage. Best Pract. Res. Clin. Gastroenterol. 27(2):171-186.
2. Montgomery, E., J.K. Field, P. Boffetta, et al. 2010. Squamous cell carcinoma of the oesophagus. In WHO Classification of Tumours of the Digestive System. F.T. Bosman, F. Carneiro, R.H. Hruba, N.D. Theise, Eds.: 18-24. Lyon: IARC.
3. Odze, R.D., J.R. Goldblum & J.M. Crawford . 2004. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas Eds.: 381-408. Philadelphia: Saunders.
4. Fenoglio-Preiser, C.M., A.E. Noffsinger, G.N. Stemmermann, et al. 2008. Gastrointestinal pathology. In An Atlas and Text. 3rd Ed.: 86-109. Philadelphia: Lippincott Williams & Wilkins.
5. Dawsey, S.M., K.J. Lewin, G.Q. Wang, et al. 1994. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer. 74(6): 1686-1692.
6. Wang, G.Q., C.C. Abnet, Q. Shen, et al. 2005. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 54(2): 187-192.
7. Mandard, A.M., P. Hainaut & M. Hollstein . 2000. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat. Res. 462(2-3): 335-342.
8. Liu, M., F. Zhang, S. Liu, et al. 2011. Loss of heterozygosity analysis of microsatellites on multiple chromosome regions in dysplasia and squamous cell carcinoma of the esophagus. Exp. Ther. Med. 2(5): 997-1001.
9. Chen, J., D.L. Kwong, T. Cao, et al. 2013. Esophageal squamous cell carcinoma (ESCC): advance in genomics and molecular genetics. Dis Esophagus doi: 10.1111/dote.12088.
10. Guo, M., J. Ren, M.G. House, et al. 2006. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 12(15): 4515-4522.
11. Riddell, R.H., H. Goldman, D.F. Ransohoff, et al. 1983. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 14(11): 931-968.
12. Levine, D.S., P.L. Blount, R.E. Rudolph & B.J. Reid . 2000. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol. 95(5): 1152-1157
13. Reid, B.J., P.L. Blount, Z. Feng & D.S. Levine . 2000. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am. J. Gastroenterol. 95(11): 3089-3096.
14. Reid, B.J., R.C. Haggitt, C.E. Rubin, et al. 1988. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum. Pathol. 19(2): 166-178.
15. Curvers, W.L., F.J. ten Kate, K.K. Krishnadath, et al. 2010. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 105(7): 1523-1530.
16. Ireland, A.P., G.W. Clark & T.R. DeMeester . 1997. Barrett's esophagus. The significance of p53 in clinical practice. Ann. Surg. 225(1): 17-30.
17. Edgren, G., H.O. Adami, E. Weiderpass & O. Nyrén . 2013. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 62: 1406.
18. Hvid-Jensen, F., L. Pedersen, A.M. Drewes, et al. 2011. Incidence of adenocarcinoma among patients with Barrett's esophagus. N. Engl. J. Med. 365: 1375.
19. Wani, S. & P. Sharma . 2006. Barrett's adenocarcinoma. GI Motility online doi:10.1038/gimo45.
20. Kuwano, H., H. Kato, T. Miyazaki, et al. 2005. Genetic alterations in esophageal cancer.Surg. Today.35:7-18.
21. Maley, C.C., P.C. Galipeau, J.C. Finley, et al. 2006. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet.38: 468-473.
22. Lanuti, M., G. Liu, J.M. Goodwin, et al. 2008. A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin. Cancer Res. 14: 3216.
23. Murray, L. & Y. Romero . 2009. Role of obesity in Barrett's esophagus and cancer. Surg. Oncol. Clin. N. Am. 18: 439-452.
24. Iijima, K., J. Grant, K. McElroy, et al. 2003. Novel mechanism of nitrosative stress from dietary nitrate with relevance to gastro-oesophageal junction cancers. Carcinogenesis. 24: 1951.
25. Richter, J.E., G.W. Falk & M.F. Vaezi . 1998. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am. J. Gastroenterol. 98: 1800-1802.
26. Zhai, R., F. Chen, G. Liu, et al. 2010. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J. Clin. Oncol. 28: 2445.
27. Sharma, P., G.W. Falk, A.P. Weston, et al. 2006. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 4: 566-572.
28. Bian, Y.S., M.C. Osterheld, F.T. Bosman, et al. 2001. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod. Pathol. 14: 397-403.
29. Kaye, P.V., S.A. Haider, M. Ilyas, et al. 2009. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistocheimisty. Histopathology 54: 699-712.
30. Skacel, M., R.E. Petras, L.A. Rybicki, et al. 2002. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am. J. Gastroenterol. 97: 2508-2513.
31. Kastelein, F., K. Biermann, E.W. Steyerberg, et al. 2013. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut. 62: 1676-1683.
32. Fitzgerald, R.C., M. di Pietro, K. Ragunath, et al. 2014. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 63(1): 7-42. doi: 10.1136/gutjnl-2013-305372. Epub 2013 Oct 28.
33. Mechref, Y., A. Hussein, S. Bekesova, et al. 2009. Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J. Proteome Res. 8: 2656-2666.
34. Mann, B., M. Madera, I. Klouckova, et al. 2010. A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma. Electrophoresis. 31: 1833-1841.
35. Bird-Lieberman, E.L., J.M. Dunn, H.G. Coleman, et al. 2012. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology 143: 927-935.
36. Tateno, H., S. Nakamura-Tsuruta & J. Hirabayashi . 2009. Comparative analysis of core-fucose-binding lectins from Lens culinaris and Pisum sativum using frontal affinity chromatography. Glycobiology 19: 527-536.
37. Brooks, S.A. 2000. The involvement of Helix pomatia lectin (HPA) binding N-acetylgalactosamine glycans in cancer progression. Histol Histopathol. 15: 143-158.
38. Yoshida, Y., T. Okamura & T. Shirakusa . 1993. An immunohistochemical study of Helix pomatia agglutinin binding on carcinoma of the esophagus. Surg. Gynecol. Obstet. 177: 299-302.
39. Bird-Lieberman, E.L., A.A. Neves, P. Lao-Sirieix, et al. 2012. Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat. Med. 18: 315-321.
40. Bertani, H., M. Frazzoni, E. DAbizzi, et al. 2013. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig. Dis. Sci. 58: 188-193.
41. Dunbar, K.B., 2011. Endomicroscopy in the evaluation of Barrett's esophagus. Curr. Opin. Gastroenterol. 27:374-382.
42. Dorer, R. & R.D. Odze . 2006. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 30(7): 871-877
43. van Schaik, F.D., B. Oldenburg, G. Offerhaus . et al. 2012. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. Inflamm. Bowel Dis. 18(3): 480-488.
44. Lisovsky, M., O. Falkowski & T. Bhuiya . 2006. Expression of alpha-methylacyl-coenzyme A racemase in dysplastic Barrett's epithelium. Hum Pathol. 37(12): 1601-1606.
45. Sträter, J., C. Wiesmüller & S. Perner, 2008. Alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry in Barrett's and colorectal mucosa: only significant overexpression favours a diagnosis of intraepithelial neoplasia. Histopathology. 52(3): 399-402.
46. Scheil-Bertram, S., D. Lorenz & C. Ell, 2008. Expression of alpha-methylacyl coenzyme A racemase in the dysplasia carcinoma sequence associated with Barrett's esophagus. Mod. Pathol. 21(8): 961-967.
47. Sonwalkar, S.A., O. Rotimi, N. Scott, et al. 2010. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase). Histopathology. 56(7): 900-907.
48. Kastelein, F., K. Biermann, E.W. Steyerberg, et al. 2013. ProBar study group. Value of α-methylacyl-CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus. Histopathology. 63(5): 630-639.